Fate Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Bob Valamehr
Chief executive officer
US$3.0m
Total compensation
| CEO salary percentage | 16.7% |
| CEO tenure | no data |
| CEO ownership | 0.07% |
| Management average tenure | less than a year |
| Board average tenure | 13.9yrs |
Recent management updates
Recent updates
We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate
Jan 06
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
Nov 20Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts
Aug 21Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Aug 11Fate Therapeutics: Looking For A Potential Turnaround In 2024
Apr 29Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 23Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%
Feb 16Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks
Jan 26Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry
Dec 19Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?
Sep 08Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price
Jun 07Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%
May 08Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Apr 17We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully
Jan 10Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation
Sep 22Fate Therapeutics: Yes For Speculators, No For Defensive Investors
Aug 30Needham initiates Fate coverage Therapeutics on potential of stem cell therapies
Jul 28Fate Therapeutics names Brian Powl as chief commercial officer
Jun 30Fate: Possible Speedy FDA Approval Process With RMAT Designation
Jun 03We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely
Jun 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$178m |
| Jun 30 2024 | n/a | n/a | -US$176m |
| Mar 31 2024 | n/a | n/a | -US$190m |
| Dec 31 2023 | US$3m | US$500k | -US$161m |
| Sep 30 2023 | n/a | n/a | -US$173m |
| Jun 30 2023 | n/a | n/a | -US$212m |
| Mar 31 2023 | n/a | n/a | -US$235m |
| Dec 31 2022 | US$3m | US$455k | -US$282m |
| Sep 30 2022 | n/a | n/a | -US$294m |
| Jun 30 2022 | n/a | n/a | -US$254m |
| Mar 31 2022 | n/a | n/a | -US$233m |
| Dec 31 2021 | US$6m | US$430k | -US$212m |
| Sep 30 2021 | n/a | n/a | -US$197m |
| Jun 30 2021 | n/a | n/a | -US$212m |
| Mar 31 2021 | n/a | n/a | -US$185m |
| Dec 31 2020 | US$2m | US$390k | -US$173m |
| Sep 30 2020 | n/a | n/a | -US$149m |
| Jun 30 2020 | n/a | n/a | -US$117m |
| Mar 31 2020 | n/a | n/a | -US$112m |
| Dec 31 2019 | US$3m | US$375k | -US$98m |
| Sep 30 2019 | n/a | n/a | -US$86m |
| Jun 30 2019 | n/a | n/a | -US$76m |
| Mar 31 2019 | n/a | n/a | -US$72m |
| Dec 31 2018 | US$3m | US$322k | -US$67m |
Compensation vs Market: Bob's total compensation ($USD2.99M) is above average for companies of similar size in the US market ($USD1.38M).
Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.
CEO
Bob Valamehr (46 yo)
no data
Tenure
US$2,986,615
Compensation
Dr. Bahram Valamehr, also known as Bob, Ph D, M.B.A., is President and CEO of Fate Therapeutics, Inc. since January 01, 2025 and was its President of Research & Development from 2024 to January 01, 2025 an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | no data | US$2.99m | 0.067% $ 142.0k | |
| Founder | less than a year | US$3.52m | 0.24% $ 512.3k | |
| Chief Legal & Compliance Officer and Corporate Secretary | 9.3yrs | US$2.82m | 0.053% $ 112.7k | |
| Chief Regulatory & Quality Officer | 3yrs | no data | 0.24% $ 516.5k | |
| Senior Vice President of Clinical Operations | less than a year | no data | no data |
1.0yrs
Average Tenure
52.5yo
Average Age
Experienced Management: FATE's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 9.3yrs | US$3.52m | 0.24% $ 512.3k | |
| Independent Chairman | 13.2yrs | US$253.25k | 0.54% $ 1.2m | |
| Independent Vice Chairman of the Board | 16.8yrs | US$218.33k | 0.27% $ 582.0k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 10.8yrs | US$228.25k | 0.010% $ 21.2k | |
| Member of Scientific Advisory Board | 14.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 14.7yrs | no data | no data | |
| Independent Director | 11.4yrs | US$231.75k | 0.058% $ 124.0k | |
| Member of Scientific Advisory Board | 14.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 14.7yrs | no data | no data | |
| Independent Director | 5.8yrs | US$227.82k | 0.0086% $ 18.4k |
13.9yrs
Average Tenure
66.5yo
Average Age
Experienced Board: FATE's board of directors are seasoned and experienced ( 13.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 00:11 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fate Therapeutics, Inc. is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Peter Lawson | Barclays |
| Etzer Darout | BMO Capital Markets Equity Research |